Drug Trial Radar · NCT07152639
Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above
Last checked: Nov 19, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,784
Planned (sponsor's estimate)
Start
Aug 9, 2025
Primary completion
May 1, 2026
Study completion Jul 1, 2026
Sponsor
- Lead sponsor
- Chengdu CoenBiotech Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Beijing Chest Hospital, Capital Medical University; Wuhan Pulmonary Hospital; Changsha Central Hospital; The First Affiliated Hospital of Xinxiang Medical College; LiuZhou People's Hospital; Wuhan Central Hospital; Yichang Central People's Hospital
- First posted
- Sep 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, blinded, active-controlled clinical trial to evaluate the effectiveness and safety of EEC in the diagnosis of Mycobacterium tuberculosis infection in people aged 3 years and above. Methods: In study 1, the marketed recombinant Mycobacterium tuberculosis fusion protein (EC) was used as a control drug in people aged 3 to 64 years. The sensitivity of EEC in participants with tuberculosis and the specificity in healthy participants and patients with non-tuberculous lung diseases were evaluated compared with recombinant Mycobacterium tuberculosis fusion protein (EC). The clinical positivity criteria of EEC were verified, and the consistency of the two detection methods, as well as the safety of EEC, were evaluated. Study 2: Triple-negative people aged 18 and above (negative in EEC, TB-PPD, and IGRA tests) were screened out from the community population and vaccinated with BCG. EEC and TB-PPD double-arm skin tests were performed 12 weeks after vaccination to evaluate whether there was a significant difference in the negative rate of EEC compared with TB-PPD after BCG vaccination in the triple-negative population. Study 3: A multicenter, positive-controlled, non-inferiority trial design was used for people aged 65 years and above, and the research hypothesis was independently tested to verify the non-inferiority of the sensitivity of this product in tuberculosis patients in this age group compared with IGRA and TB-PPD, as well as the consistency of the diagnostic results of IGRA with non-tuberculous lung diseases and the general community population. At the same time, attention was paid to and analysis of the specificity and safety of EEC in people aged 65 years and above.
Conditions
- Tuberculosis
Interventions
5μg/ml EECBiological
0.1ml, one time, containing high dose 5μg/ml of active ingredients
5 unit(U) ECBiological
0.1 ml , one time, containing 5U of active ingredients
5 IU TB-PPDBiological
0.1 ml , one time, containing 5IU of active ingredients
IGRADiagnostic test
96-well/plate x 2 plates; 100 tubes/box x 1 box
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity (true positive rate) of EEC and EC detection methods in tuberculosis patients aged 3 to 64 yearsTime frame: 7 days after injection
- Specificity (true negative rate) of EEC and EC detection methods in patients with non-tuberculous lung diseases aged 3 to 64 yearsTime frame: 7 days after injection
- Specificity (true negative rate) of EEC and EC for the diagnosis of Mycobacterium tuberculosis infection in healthy participants aged 3-64 years .Time frame: 7 days after injection
- Negative rate of EEC test drug and TB-PPD control drug in BCG-vaccinated population in triple-negative populationTime frame: 7 days after second injection
- Sensitivity (true positive rate) of EEC test drug versus control IGRA and TB-PPD for assisting clinical diagnosis of tuberculosis in people aged 65 years and older with tuberculosisTime frame: 7 days after injection
- To evaluate the consistency (accordance rate) of the diagnostic results of EEC and IGRA in non-tuberculous lung diseases in the general community population aged 65 years and aboveTime frame: 7 days after injection
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chest Hospital
Beijing, Beijing Municipality, China · Recruiting
Changsha Center Hospital
Hunan, Changsha, China · Recruiting
LiuZhou People's Hospital
Liuzhou, Guangxi, China · Recruiting
The First Affiliated Hospital of Xinxiang Medical College
Xinxiang, Henan, China · Not yet recruiting
Wuhan Pulmonary Hospital
Wuhan, Hubei, China · Recruiting
Wuhan Central Hospital
Wuhan, Hubei, China · Recruiting
Yichang Central People's Hospital
Yichang, Hubei, China · Recruiting
Public health clinical center of chengdu
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.